Edwards Lifesciences Corporation (NYSE:EW) VP Donald E. Bobo, Jr. sold 5,300 shares of the company’s stock in a transaction dated Wednesday, November 29th. The shares were sold at an average price of $116.45, for a total value of $617,185.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Donald E. Bobo, Jr. also recently made the following trade(s):

  • On Monday, October 30th, Donald E. Bobo, Jr. sold 5,300 shares of Edwards Lifesciences stock. The shares were sold at an average price of $101.12, for a total value of $535,936.00.
  • On Friday, September 29th, Donald E. Bobo, Jr. sold 5,300 shares of Edwards Lifesciences stock. The shares were sold at an average price of $108.86, for a total value of $576,958.00.

Edwards Lifesciences Corporation (NYSE:EW) traded down $0.79 on Friday, reaching $116.41. The company had a trading volume of 1,993,419 shares, compared to its average volume of 1,312,462. The company has a market cap of $24,801.85, a P/E ratio of 32.47, a PEG ratio of 2.10 and a beta of 0.50. The company has a debt-to-equity ratio of 0.33, a current ratio of 3.49 and a quick ratio of 2.76. Edwards Lifesciences Corporation has a twelve month low of $81.25 and a twelve month high of $121.45.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, October 24th. The medical research company reported $0.84 EPS for the quarter, missing analysts’ consensus estimates of $0.86 by ($0.02). Edwards Lifesciences had a return on equity of 27.22% and a net margin of 22.47%. The business had revenue of $821.50 million for the quarter, compared to analyst estimates of $833.85 million. During the same period last year, the firm posted $0.68 EPS. Edwards Lifesciences’s quarterly revenue was up 11.1% on a year-over-year basis. sell-side analysts predict that Edwards Lifesciences Corporation will post 3.75 EPS for the current year.

EW has been the topic of a number of research reports. Canaccord Genuity restated a “buy” rating and issued a $155.00 price objective on shares of Edwards Lifesciences in a report on Sunday, October 8th. Cowen reissued a “buy” rating and issued a $135.00 price objective on shares of Edwards Lifesciences in a research report on Thursday, October 12th. Barclays reduced their price objective on Edwards Lifesciences from $120.00 to $118.00 and set an “equal weight” rating for the company in a research report on Wednesday, October 25th. BidaskClub cut Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Friday, August 25th. Finally, Royal Bank Of Canada restated a “buy” rating and issued a $130.00 target price on shares of Edwards Lifesciences in a research note on Friday, September 1st. Seven research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $125.53.

Several institutional investors have recently made changes to their positions in EW. ETF Managers Group LLC bought a new position in Edwards Lifesciences in the second quarter worth approximately $112,000. Shine Investment Advisory Services Inc. bought a new position in Edwards Lifesciences in the second quarter worth approximately $126,000. MPS Loria Financial Planners LLC bought a new position in Edwards Lifesciences in the second quarter worth approximately $140,000. Dupont Capital Management Corp bought a new position in Edwards Lifesciences in the third quarter worth approximately $142,000. Finally, Captrust Financial Advisors purchased a new stake in shares of Edwards Lifesciences in the second quarter worth approximately $149,000. Institutional investors own 81.55% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/12/02/donald-e-bobo-jr-sells-5300-shares-of-edwards-lifesciences-corporation-ew-stock.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Stock Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related stocks with our FREE daily email newsletter.